Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC

ArteraAI MMAI enhances prediction of biochemical recurrence and metastasis in localised prostate cancer

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC

ASCO GU 2026: Updates in renal cancer

ASCO GU 2026: Updates in bladder cancer

ASCO GU 2026: Updates in metastatic prostate cancer

ASCO GU 2026: Updates in localised prostate cancer

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Evaluation and definition of response and progression from trials to clinical practice

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer

Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies